ZHONGSHENGYAOYE: The first participant has been enrolled in the Phase III clinical trial of RAY1225 injection for glycemic reduction
ZHONGSHENGYAOYE announced that its holding subsidiary ZHONGSHENGRUICHUANG has completed the enrollment and administration of the first participant in two Phase III clinical trials for the innovative peptide drug RAY1225 injection, which is independently developed. RAY1225 injection is a peptide drug with global independent intellectual property rights and has the potential for long-acting administration every two weeks. ZHONGSHENGRUICHUANG will continue to advance the Phase III clinical trials of RAY1225 injection, striving to complete the relevant research and apply for drug market approval as soon as possible
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments